Drug-induced oxidative haemolysis.
D000042:Absorption; D058186:Acute Kidney Injury / Q000150:complications; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D004220:Disulfides / Q000378:metabolism; D004910:Erythrocyte Membrane / Q000378:metabolism; D005260:Female; D005914:Globins / Q000378:metabolism; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000151:congenital; D006453:Hemoglobinopathies / Q000139:chemically induced; D006454:Hemoglobins / Q000378:metabolism; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D050356:Lipid Metabolism; D008297:Male; D008706:Methemoglobin / Q000378:metabolism; D008708:Methemoglobinemia / Q000150:complications; D010084:Oxidation-Reduction; D010615:Phenacetin / Q000009:adverse effects; D013435:Sulfhemoglobin / Q000378:metabolism; D013449:Sulfonamides / Q000009:adverse effects
D004220:Disulfides; D006454:Hemoglobins; D013449:Sulfonamides; D005914:Globins; D008706:Methemoglobin; D013435:Sulfhemoglobin; D010615:Phenacetin